Multiple Presentations to Highlight Longer-Term Clinical Data and Real-World Experience in Support of Aquablation Therapy at AUA 2019

REDWOOD SHORES, Calif.--(BUSINESS WIRE)-- PROCEPT® BioRobotics announced today that two pivotal studies and one all-comers commercial series featuring the company’s Aquablation^® therapy for the treatment of benign prostatic hyperplasia (BPH) will be presented at the American Urological Association (AUA) Annual Meeting at McCormick Place in Chicago, May 3 - 6, 2019. Aquablation therapy, delivered by the AquaBeam® Robotic System, is the only FDA cleared, autonomous robot for surgery.

PD10-12 “WATER II: Aquablation Therapy for Benign Prostatic Hyperplasia in Men with Large Prostates (80-150 mL): One-Year Safety and Efficacy Results”
May 3, 11:20 - 11:30 a.m.
One-year data from the WATER II Study (Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue), evaluating the safety and efficacy of Aquablation therapy in 101 men with large prostates 80 to 150 milliliters (mL) in size, will be presented by Naeem Bhojani, M.D., associate professor at the Université de Montréal, Montréal, Canada. The podium session PD10-12, titled “WATER II: Aquablation Therapy for Benign Prostatic Hyperplasia in Men with Large Prostates (80-150 mL): One-Year Safety and Efficacy Results,” follows the release of WATER II six-month data at the European Association of Urology Annual (EAU) Congress in March, which determined that Aquablation therapy is a safe surgical alternative for treating men with large prostates, where surgical options are limited.

MP45-11 “The WATER Study Clinical Results – Results at Two Years and Urodynamic Findings”
May 4, 3:30 - 5:30 p.m.
Two-year follow-up data from the WATER Study, which compared the safety and efficacy of Aquablation therapy to the most common BPH surgical method, transurethral resection of the prostate (TURP), in 181 men with prostates between 30 and 80 mL in size, will be presented by Peter Gilling, M.D., co-principal investigator and professor of surgery at the University of Auckland, Bay of Plenty Clinical School Tauranga, New Zealand. The moderated poster MP45-11 titled, “The WATER Study Clinical Results – Results at Two Years and Urodynamic Findings,” will build on WATER Study one-year data featured at AUA 2018, which demonstrated similar durable outcomes at one year compared to TURP, a low retreatment rate and symptom improvement scores comparable to other resective techniques. Dr. Gilling recently received two awards at the USANZ annual conference related to this data set.

MP45-10 “Real-life Data From 180 Consecutive Patients Undergoing Aquablation of the Prostate”
May 4, 3:30 - 5:30 p.m.
A third study, “Real-life Data From 180 Consecutive Patients Undergoing Aquablation of the Prostate,” will be presented by Prof. Thorsten Bach, chief physician in urology at Asklepios Hospital Harburg in Hamburg, Germany. The moderated poster MP45-10 will highlight single-center results of a consecutive, 180-patient cohort treated with Aquablation therapy between September 2017 and June 2018.

“These clinical presentations validate the durability, superior safety and gold standard-like effectiveness of Aquablation therapy in a broad range of prostates along with a large data set of real-world experience. We are thrilled to present this robust set of clinical data at AUA in Chicago,” said Nikolai Aljuri, Ph.D., PROCEPT BioRobotics, president and chief executive officer. “BPH is a condition that affects millions of men worldwide, and yet relatively few patients elect to treat their BPH with surgery due to potential complications. With Aquablation therapy, we offer patients a heat-free, minimally invasive and robotically controlled treatment option that helps alleviate their concerns and provides safe and effective symptom relief.”

For more information about Aquablation therapy, visit PROCEPT BioRobotics at AUA Booth #4027 at McCormick Place.

About PROCEPT BioRobotics
Based in Silicon Valley, PROCEPT BioRobotics is a privately-held surgical robotics company enabling better patient care by developing transformative solutions in urology. The company offers the world’s first commercially available minimally invasive surgical robot providing autonomous tissue removal to safely and effectively treat BPH. Aquablation therapy, delivered by the AquaBeam® Robotic System, combines the clarity of real-time, multi-dimensional imaging, autonomous robotics and heat-free waterjet ablation for targeted, controlled, and immediate removal of prostate tissue for the treatment of lower urinary tract symptoms (LUTS) caused by BPH. The therapy offers predictable and reproducible outcomes, independent of prostate anatomy, prostate size or surgeon experience. For more information, visit http://www.PROCEPT-BioRobotics.com.

Important Safety Information
All surgical treatments have inherent and associated side effects. The most common side effects are mild and transient, and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. For more information about potential side effects and risks associated with Aquablation therapy, speak with your urologist or surgeon. No claim is made that the AQUABEAM Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190501005323/en/